| Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses TP Sheahan, AC Sims, RL Graham, VD Menachery, LE Gralinski, ... Science translational medicine 9 (396), eaal3653, 2017 | 1926 | 2017 |
| Return of the Coronavirus: 2019-nCoV LE Gralinski, VD Menachery Viruses 12 (2), 135, 2020 | 1874 | 2020 |
| Spike mutation D614G alters SARS-CoV-2 fitness JA Plante, Y Liu, J Liu, H Xia, BA Johnson, KG Lokugamage, X Zhang, ... Nature 592 (7852), 116-121, 2021 | 1778 | 2021 |
| A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence VD Menachery, BL Yount, K Debbink, S Agnihothram, LE Gralinski, ... Nature medicine 21 (12), 1508-1513, 2015 | 1249 | 2015 |
| Evasion of type I interferon by SARS-CoV-2 H Xia, Z Cao, X Xie, X Zhang, JYC Chen, H Wang, VD Menachery, ... Cell reports 33 (1), 2020 | 952 | 2020 |
| Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19 N Doria-Rose, MS Suthar, M Makowski, S O’Connell, AB McDermott, ... New England Journal of Medicine 384 (23), 2259-2261, 2021 | 718 | 2021 |
| Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis BA Johnson, X Xie, AL Bailey, B Kalveram, KG Lokugamage, A Muruato, ... Nature 591 (7849), 293-299, 2021 | 681 | 2021 |
| An infectious cDNA clone of SARS-CoV-2 X Xie, A Muruato, KG Lokugamage, K Narayanan, X Zhang, J Zou, J Liu, ... Cell host & microbe 27 (5), 841-848. e3, 2020 | 669 | 2020 |
| Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera X Xie, Y Liu, J Liu, X Zhang, J Zou, CR Fontes-Garfias, H Xia, ... Nature medicine 27 (4), 620-621, 2021 | 667 | 2021 |
| Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States J Harcourt, A Tamin, X Lu, S Kamili, SK Sakthivel, J Murray, K Queen, ... Emerging infectious diseases 26 (6), 1266, 2020 | 664 | 2020 |
| Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis LE Gralinski, TP Sheahan, TE Morrison, VD Menachery, K Jensen, ... MBio 9 (5), 10.1128/mbio. 01753-18, 2018 | 615 | 2018 |
| Rapid generation of neutralizing antibody responses in COVID-19 patients MS Suthar, MG Zimmerman, RC Kauffman, G Mantus, SL Linderman, ... Cell Reports Medicine 1 (3), 2020 | 586 | 2020 |
| Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants A Pegu, SE O’Connell, SD Schmidt, S O’Dell, CA Talana, L Lai, J Albert, ... Science 373 (6561), 1372-1377, 2021 | 581 | 2021 |
| SARS-like WIV1-CoV poised for human emergence VD Menachery, BL Yount Jr, AC Sims, K Debbink, SS Agnihothram, ... Proceedings of the National Academy of Sciences 113 (11), 3048-3053, 2016 | 488 | 2016 |
| The N501Y spike substitution enhances SARS-CoV-2 infection and transmission Y Liu, J Liu, KS Plante, JA Plante, X Xie, X Zhang, Z Ku, Z An, D Scharton, ... Nature 602 (7896), 294-299, 2022 | 424 | 2022 |
| LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants K Westendorf, S Žentelis, L Wang, D Foster, P Vaillancourt, M Wiggin, ... Cell reports 39 (7), 2022 | 422 | 2022 |
| Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant Y Liu, J Liu, BA Johnson, H Xia, Z Ku, C Schindewolf, SG Widen, Z An, ... Cell reports 39 (7), 2022 | 408 | 2022 |
| The variant gambit: COVID-19’s next move JA Plante, BM Mitchell, KS Plante, K Debbink, SC Weaver, VD Menachery Cell host & microbe 29 (4), 508-515, 2021 | 376 | 2021 |
| Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV KG Lokugamage, A Hage, M de Vries, AM Valero-Jimenez, ... Journal of virology 94 (23), 10.1128/jvi. 01410-20, 2020 | 369 | 2020 |
| A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation AE Muruato, CR Fontes-Garfias, P Ren, MA Garcia-Blanco, ... Nature communications 11 (1), 4059, 2020 | 345 | 2020 |